Market Place
Sourcing Support
Hikal Q2 FY25 revenue stood at Rs. 453 Cr
13 Nov 2024 //
INDPHARMAPOST
Hikal shareholders approve reappointment of Sugandha Hiremath on the board
17 Sep 2024 //
MONEYCONTROL
Hiremath-Kalyani fight over Hikal takes a new turn
04 May 2023 //
ECONOMICTIMES
Supriya Lifescience gets reality check; Hikal back in demand after 11 sessions
21 Jan 2022 //
ECONOMICTIMES
Pharma shares under pressure; Aurobindo, Wockhardt, Hikal, Natco down 6%
20 Aug 2021 //
BUSINESS STANDARD
Hikal Q1 net profit rises 236% at Rs. 51 crore
06 Aug 2021 //
PHARMABIZ
Hikal inks 10-year multi-product deal with global pharma company for APIs
05 May 2021 //
ECONOMICTIMES
BSE Healthcare index hits record high; Laurus Labs, Dr Reddy`s at new highs
17 Sep 2020 //
BUSINESS STANDARD
Hikal develops Favipiravir API, its intermediates
15 May 2020 //
PRESS RELEASE
Hikal freezes at 5% upper circuit on development of Favipiravir API
14 May 2020 //
BUSINESS-STANDARD
Hikal contributes to the COVID-19 crisis through various community welfare
27 Apr 2020 //
FREE PRESS JOURNAL
Hikal Ltd resume operations, stock locks in upper circuit
07 Apr 2020 //
DSIJ
Apotex`s Generic Carfilzomib Receive Approval in U.S
30 Mar 2020 //
FDA
Hikal`s Generic Pregabalin Receives Approval in US
28 Mar 2020 //
FDA
Should You Worry About Hikal Limited’s (NSE:HIKAL) CEO Salary Level?
25 Mar 2020 //
SIMPLYWALL
Hikal clarifies Mahad unit is operating normally
12 Mar 2020 //
BUSINESS-STANDARD
Hikal share price slips nearly 8% after MPCB notice to close Mahad unit
09 Mar 2020 //
MONEY CONTROL
MPCB issues closure notice to HIKAL Ltd for its Mahad Unit
06 Mar 2020 //
EQUITYBULLS
Hikal gets plant closure notice from Maharashtra Pollution stock dips 7.5%
06 Feb 2020 //
INDIAINFOLINE
Hikal spurts after Gujarat facilty gets EIR from USFDA
12 Dec 2019 //
BUSINESS-STANDARD
Hikal receives zero observation from US FDA for Panoli facility
12 Dec 2019 //
PHARMABIZ
EIR Report Received from the USFDA Inspection of Pharma Facility at Panoli
20 Mar 2019 //
PRESS RELEASE
Inspection at Jigani, Banglore by PMDA
17 Aug 2018 //
PRESS RELEASE
Hikal soars as USFDA issues `Zero` 483 observations for Bangalore facility
10 Jan 2016 //
BUSINESS STANDARD
Indian pharma`s struggle to tighten standards paves way for M&A deals | Reuters
29 Jun 2015 //
DRUG REGULATIONS
HIKAL: Turnover For 9M FY 2015 Up By 9% To Rs. 658 Crores
29 Jan 2015 //
HIKAL
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.